Home Cart Sign in  
Chemical Structure| 903895-98-7 Chemical Structure| 903895-98-7

Structure of FPR Agonist 43
CAS No.: 903895-98-7

Chemical Structure| 903895-98-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

FPR Agonist 43 is an effective dual agonist of formyl peptide receptor 1 (FPR1) and formyl peptide receptor 2 (FPR2)/ALX.

Synonyms: TC-FPR 43

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of FPR Agonist 43

CAS No. :903895-98-7
Formula : C20H21ClN4O2
M.W : 384.86
SMILES Code : O=C(NC1=C(C(C)C)N(C)N(C2=CC=CC=C2)C1=O)NC3=CC=C(Cl)C=C3
Synonyms :
TC-FPR 43
MDL No. :MFCD30182236

Safety of FPR Agonist 43

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

Description
FPR Agonist 43 is a dual agonist for the formyl peptide receptor 1 (FPR1) and formyl peptide receptor 2 (FPR2)/ALX, exhibits robust activity[1].[2].

In Vitro:

Cell Line
Concentration Treated Time Description References
HL-60 cells 1.8 μM (EC50) 15 min To evaluate the effect of Cmpd43 on oxidative burst activity, showing activation via FPR2. JACC Basic Transl Sci. 2019 Nov 13;4(8):905-920
Peritoneal macrophages 0.1 pM (EC50) 15 min pretreatment, 45 min phagocytosis assay To assess the effect of Cmpd43 on macrophage phagocytosis, showing significant enhancement via FPR2. JACC Basic Transl Sci. 2019 Nov 13;4(8):905-920
Rat cardiomyocytes 1 μM 48 hours To evaluate the cardioprotective effects of FPR agonists on simulated ischemia-reperfusion injury in cardiomyocytes, results showed that Cmpd43 lacked cardioprotective effects Nat Commun. 2017 Feb 7;8:14232
CHO cells stably transfected with human FPR2 10 μM 5 minutes To evaluate the signaling properties of FPR agonists in hFPR2-CHO cells, results showed that Cmpd43 induced ERK1/2 phosphorylation in hFPR2-CHO cells Nat Commun. 2017 Feb 7;8:14232
CHO cells stably transfected with human FPR1 10 μM 5 minutes To evaluate the signaling properties of FPR agonists in hFPR1-CHO cells, results showed that Cmpd43 induced ERK1/2 phosphorylation in hFPR1-CHO cells Nat Commun. 2017 Feb 7;8:14232
Human THP-1 macrophages 30 μM Overnight To evaluate the inhibitory effect of Cpd43 on LPS-induced IL-6 secretion Br J Pharmacol. 2014 Sep;171(17):4087-96
Human RA FLS 30 μM 4 hours To evaluate the inhibitory effect of Cpd43 on IL-6 secretion Br J Pharmacol. 2014 Sep;171(17):4087-96
Mouse bone marrow macrophages 1, 10, and 30 μM 7 days To evaluate the inhibitory effect of Cpd43 on RANKL-induced osteoclastogenesis Br J Pharmacol. 2014 Sep;171(17):4087-96
RAW 264.7 cells 1, 10, and 30 μM 7 days To evaluate the inhibitory effect of Cpd43 on RANKL-induced osteoclastogenesis Br J Pharmacol. 2014 Sep;171(17):4087-96
Mouse whole blood neutrophils 0.1-10 μM 30 minutes Reduced CXCR2 expression on the cell surface Immunology. 2011 Mar;132(3):441-50
Mouse bone marrow-derived neutrophils 0.1-10 μM 30 minutes Reduced CXCR2 expression on the cell surface Immunology. 2011 Mar;132(3):441-50
Human polymorphonuclear leukocytes 1 μM 5 minutes To evaluate the desensitization effect of C43 on FPR2/ALX in neutrophils J Biol Chem. 2012 Jul 13;287(29):24690-7
HEK293 cells 1 μM To assess calcium mobilization and ERK phosphorylation upon FPR2/ALX activation J Biol Chem. 2012 Jul 13;287(29):24690-7

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Myocardial infarction model (permanent LAD artery occlusion) Oral gavage 1 mg/kg and 10 mg/kg Once daily for 4 weeks To evaluate the effects of long-term oral Cmpd43 treatment on cardiac structure and function post-MI, showing improved LV function and reduced remodeling. JACC Basic Transl Sci. 2019 Nov 13;4(8):905-920
C57BL/6 mice Myocardial ischemia-reperfusion injury model Intraperitoneal injection 50 mg/kg Once daily for 24 hours or 7 days To evaluate the cardioprotective effects of FPR agonists on myocardial ischemia-reperfusion injury, results showed that Cmpd43 lacked cardioprotective actions Nat Commun. 2017 Feb 7;8:14232
Mice K/BxN serum transfer arthritis model Intraperitoneal injection 6 or 30 mg·kg−1 Once daily for 4 days To evaluate the inhibitory effect of Cpd43 on arthritis development Br J Pharmacol. 2014 Sep;171(17):4087-96
BALB/c mice LPS-induced neutrophil migration model in airways Oral 3, 10, 30, 100 mg/kg Single dose, 15 minutes before LPS exposure Dose-dependent reduction in neutrophil counts in BALF, inhibited neutrophil migration Immunology. 2011 Mar;132(3):441-50

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.60mL

0.52mL

0.26mL

12.99mL

2.60mL

1.30mL

25.98mL

5.20mL

2.60mL

References

 

Historical Records

Categories